Cellectis U.S. Listed Shares up 3.5% at $2.66 After the Bell After Receives Orphan Drug Designation for Allogeneic Car T Product for Patients With Acute Lymphoblastic Leukemia
在收盤後,Cellectis公司美國上市股票上漲3.5%,至2.66美元,此前該公司收到了抗原異基因T細胞產品治療急性淋巴細胞白血病孤兒藥物認定。
Cellectis U.S. Listed Shares up 3.5% at $2.66 After the Bell After Receives Orphan Drug Designation for Allogeneic Car T Product for Patients With Acute Lymphoblastic Leukemia
在收盤後,Cellectis公司美國上市股票上漲3.5%,至2.66美元,此前該公司收到了抗原異基因T細胞產品治療急性淋巴細胞白血病孤兒藥物認定。
譯文內容由第三人軟體翻譯。